Glaucoma News

NEW YORK — In this Healio Video Perspective from OSN New York, Nandini Venkateswaran, MD, of Massachusetts Eye and Ear Infirmary, discusses real-world data investigating the use of Dextenza in patients with glaucoma.

November is Diabetes-related Eye Disease Awareness Month, and early detection and treatment of diabetes are key to reduce the risk for significant vision loss and blindness, according to Prevent Blindness.

CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Alex Long of Alcon introduces some of the company’s technologies, including the Voyager direct selective laser trabeculoplasty device.

An estimated 4.22 million U.S. adults had glaucoma in 2022, and 1.49 million had vision-affecting glaucoma, with “substantial variation” in prevalence by region and demographics, according to a study published in JAMA Ophthalmology.

CHICAGO — In this Healio Video Perspective from the AAO meeting, Savak Teymoorian, MD, MBA, discusses the benefits of interventional glaucoma.

CHICAGO — Mitigating overtreatment in glaucoma requires a willingness to wait to treat patients, which can be cultivated by embracing the uncertainty of common glaucoma measurements, according to a speaker here.

CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Patrick Mooney, CEO of Spyglass Pharma, discusses the company’s IOL-based bimatoprost drug delivery platform for patients with open-angle glaucoma or ocular hypertension.

Use of glucagon-like peptide-1 receptor agonists was associated with a 19% reduction in risk for glaucoma in patients with type 2 diabetes, with longer use extending the protective association, according to a study in Ophthalmology.

Concurrent use of a beta-blocker with Simbrinza delayed the onset of ocular allergy and may extend treatment duration and adherence among patients with glaucoma, according to a retrospective study in BMC Ophthalmology.